Meloxicam (Tablets, Solution, Gel, Suppositories) Instructions for Use

Instructions
Dosage forms

ATC Code

M01AC06 (Meloxicam)

Active Substance

Meloxicam (Rec.INN registered by WHO)

Clinical-Pharmacological Group

NSAID. Selective COX-2 inhibitor

Pharmacotherapeutic Group

Anti-inflammatory and antirheumatic drugs; non-steroidal anti-inflammatory and antirheumatic drugs; oxicams

Pharmacological Action

NSAID, an enolic acid derivative, has anti-inflammatory, analgesic, and antipyretic effects.

The mechanism of the anti-inflammatory action of meloxicam consists in its ability to inhibit the synthesis of prostaglandins, known mediators of inflammation.

Meloxicam in vivo inhibits the synthesis of prostaglandins at the site of inflammation to a greater extent than in the gastric mucosa or kidneys. These differences are associated with more selective inhibition of COX-2 compared to COX-1. It is believed that inhibition of COX-2 provides the therapeutic actions of NSAIDs, whereas inhibition of the constantly present isoenzyme COX-1 may be responsible for side effects from the stomach and kidneys. The selectivity of meloxicam for COX-2 has been confirmed in various test systems, both in vitro and in vivo. The selective ability of meloxicam to inhibit COX-2 was demonstrated using human whole blood in vitro as a test system. It was found that Meloxicam (in doses of 7.5 mg and 15 mg) more actively inhibited COX-2, exerting a greater inhibitory effect on the production of prostaglandin E₂ stimulated by lipopolysaccharide (a reaction controlled by COX-2) than on the production of thromboxane involved in the blood clotting process (a reaction controlled by COX-1). These effects were dose-dependent.

Ex vivo studies have shown that Meloxicam (in doses of 7.5 mg and 15 mg) does not affect platelet aggregation and bleeding time.

In clinical studies, gastrointestinal side effects overall occurred less frequently with meloxicam at doses of 7.5 and 15 mg than with other NSAIDs with which it was compared. This difference in the frequency of gastrointestinal side effects is mainly due to the fact that phenomena such as dyspepsia, vomiting, nausea, and abdominal pain were observed less frequently with meloxicam. The frequency of perforations in the upper gastrointestinal tract, ulcers, and bleeding associated with the use of meloxicam was low and dose-dependent.

Pharmacokinetics

Meloxicam is well absorbed from the gastrointestinal tract, as evidenced by its high absolute bioavailability (90%) after oral administration. After a single use of meloxicam, C_max in plasma is reached within 5-6 hours. Concurrent intake of food and inorganic antacids does not alter absorption. When taken orally (in doses of 7.5 and 15 mg), the concentration of meloxicam is proportional to the dose. Steady-state pharmacokinetics are achieved within 3-5 days. The range of differences between C_max and C_min of meloxicam after its administration once daily is relatively small and is 0.4-1.0 µg/ml when using a dose of 7.5 mg, and when using a dose of 15 mg – 0.8-2.0 µg/ml (C_min and C_max values during the steady-state pharmacokinetic period are given, respectively), although values outside this range have also been noted. C_max in plasma during the steady-state pharmacokinetic period is reached 5-6 hours after oral administration.

Meloxicam is highly bound to plasma proteins, mainly albumin (99%). It penetrates into the synovial fluid, the concentration in the synovial fluid is approximately 50% of the plasma concentration. V_d after multiple oral administration of meloxicam (in doses from 7.5 mg to 15 mg) is about 16 L, with a coefficient of variation from 11 to 32%. Interindividual differences range from 7-20%.

Meloxicam is almost completely metabolized in the liver to form 4 pharmacologically inactive derivatives. The main metabolite, 5'-carboxymeloxicam (60% of the dose), is formed by oxidation of an intermediate metabolite, 5'-hydroxymethylmeloxicam, which is also excreted, but to a lesser extent (9% of the dose). In vitro studies have shown that the isoenzyme CYP2C9 plays an important role in this metabolic transformation, with the isoenzyme CYP3A4 having additional significance. Peroxidase, whose activity probably varies individually, is involved in the formation of two other metabolites (accounting for 16% and 4% of the dose, respectively).

It is excreted equally through the intestine and kidneys, mainly in the form of metabolites. Less than 5% of the daily dose is excreted unchanged in the feces; in urine, Meloxicam is detected only in trace amounts in unchanged form. The average T_1/2 of meloxicam varies from 13 to 25 hours. Plasma clearance averages 7-12 ml/min after a single use.

Indications

Symptomatic treatment: osteoarthritis (arthrosis, degenerative joint diseases), including with a pain component; rheumatoid arthritis; ankylosing spondylitis; other inflammatory and degenerative diseases of the musculoskeletal system, such as arthropathies, dorsopathies (e.g., sciatica, low back pain, shoulder periarthritis), accompanied by pain.

ICD codes

Open the list of ICD codes

ICD-10 code	Indication
M05	Seropositive rheumatoid arthritis
M13.9	Arthritis, unspecified
M15	Polyosteoarthritis
M19.9	Unspecified arthrosis
M25.5	Pain in joint
M42	Spinal osteochondrosis
M45	Ankylosing spondylitis
M47	Spondylosis
M54.1	Radiculopathy
M54.3	Sciatica
M54.4	Lumbago with sciatica
M75.0	Adhesive capsulitis of shoulder
R52.0	Acute pain
R52.2	Other chronic pain

ICD-11 code	Indication
8B93.Z	Radiculopathy, unspecified
8E4A.1	Paraneoplastic or autoimmune diseases of the peripheral or autonomic nervous system
FA05	Polyosteoarthritis
FA0Z	Osteoarthritis, unspecified
FA20.0	Seropositive rheumatoid arthritis
FA2Z	Inflammatory arthropathies, unspecified
FA85.Z	Defects of vertebral end-plates, unspecified
FA8Z	Degenerative disease of spine, unspecified
FA92.0Z	Ankylosing spondylitis, unspecified
FB53.0	Adhesive capsulitis of shoulder
ME82	Pain in joint
ME84.20	Lumbago with sciatica
ME84.3	Sciatica
MG30.Z	Chronic pain syndrome, unspecified
MG31.Z	Acute pain, unspecified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Tablets

The drug is taken orally with food at a daily dose of 7.5-15 mg.

Recommended dosing regimen

Rheumatoid arthritis 15 mg per day. Depending on the therapeutic effect, the dose can be reduced to 7.5 mg per day.

Osteoarthritis 7.5 mg per day. If ineffective, the dose can be increased to 15 mg per day.

Ankylosing spondylitis 15 mg per day. The maximum daily dose should not exceed 15 mg.

In patients with an increased risk of side effects, as well as in patients with severe renal failure on hemodialysis, the dose should not exceed 7.5 mg per day.

Solution

Set individually, depending on the intensity of pain and the severity of the inflammatory process. Administer intramuscularly at a dose of 7.5 mg or 15 mg once a day.

Suppositories

Rectally at a dose of 7.5-15 mg once a day.

Gel

Apply externally. Apply to the skin over the affected area 2 times a day.

The duration of the course of therapy is determined individually, may vary depending on the location of the lesion and the observed therapeutic effect, and is no more than 4 weeks.

Adverse Reactions

From the hematopoietic system infrequently – anemia; rarely – leukopenia, thrombocytopenia, changes in blood cell counts, including changes in the leukocyte formula.

From the immune system infrequently – immediate hypersensitivity reactions; frequency not established – anaphylactic shock, anaphylactoid reactions.

Mental disorders rarely – mood changes; frequency not established – confusion, disorientation.

From the nervous system often – headache; infrequently – dizziness, drowsiness.

From the sensory organs infrequently – vertigo; rarely – conjunctivitis, visual disturbances, including blurred vision, tinnitus.

From the cardiovascular system infrequently – increased blood pressure, feeling of “flushing” of the face; rarely – palpitations.

From the respiratory system rarely – bronchial asthma in patients allergic to acetylsalicylic acid and other NSAIDs.

From the digestive system often – abdominal pain, dyspepsia, diarrhea, nausea, vomiting; infrequently – occult or overt gastrointestinal bleeding, gastritis, stomatitis, constipation, flatulence, belching; rarely – gastroduodenal ulcers, colitis, esophagitis; very rarely – gastrointestinal perforation.

From the liver and biliary tract infrequently – transient changes in liver function parameters (e.g., increased activity of transaminases or bilirubin concentration); very rarely – hepatitis.

From the skin and subcutaneous tissues infrequently – angioedema, itching, skin rash; rarely – toxic epidermal necrolysis, Stevens-Johnson syndrome, urticaria; very rarely – bullous dermatitis, erythema multiforme; frequency not established – photosensitivity.

From the urinary system infrequently – changes in renal function parameters (increased serum creatinine and/or urea concentration), urination disorders, including acute urinary retention; very rarely – acute renal failure.

From the reproductive system infrequently – delayed ovulation; frequency not established – infertility in women.

Other: infrequently – edema.

Concomitant use with drugs that suppress bone marrow (e.g., methotrexate) may provoke cytopenia.

Gastrointestinal bleeding, ulcer, or perforation can be fatal.

As with other NSAIDs, the possibility of interstitial nephritis, glomerulonephritis, renal medullary necrosis, and nephrotic syndrome cannot be ruled out.

Contraindications

Hypersensitivity to meloxicam; hypersensitivity (including to other NSAIDs); complete or incomplete combination of bronchial asthma, recurrent polyposis of the nose or paranasal sinuses, angioedema or urticaria caused by intolerance to acetylsalicylic acid or other NSAIDs due to the existing probability of cross-sensitivity (including in history); erosive and ulcerative lesions of the stomach and duodenum in the acute stage or recently suffered; inflammatory bowel diseases (Crohn’s disease or ulcerative colitis in the acute stage); severe hepatic and heart failure; severe renal failure (if hemodialysis is not performed, CrCl <30 ml/min, as well as with confirmed hyperkalemia); active liver disease; active gastrointestinal bleeding, recently suffered cerebrovascular bleeding or established diagnosis of blood clotting system diseases; concomitant therapy with anticoagulants, because there is a risk of intramuscular hematoma formation; therapy of perioperative pain during coronary artery bypass surgery; pregnancy; lactation period (breastfeeding); children under 12 years of age.

With caution

History of gastrointestinal diseases (presence of Helicobacter pylori infection); congestive heart failure; renal failure (CrCl 30-60 ml/min); coronary artery disease; cerebrovascular diseases; dyslipidemia/hyperlipidemia; diabetes mellitus; concomitant therapy with the following drugs: anticoagulants, oral corticosteroids, antiplatelet agents, selective serotonin reuptake inhibitors; peripheral arterial diseases; elderly age; long-term use of NSAIDs; smoking; frequent alcohol consumption.

Use in Pregnancy and Lactation

Contraindicated for use during pregnancy and breastfeeding.

Use in Hepatic Impairment

Contraindicated for use in severe hepatic insufficiency, active liver disease.

In patients with liver cirrhosis (compensated), dose adjustment is not required.

Use in Renal Impairment

Contraindicated for use in severe renal failure (if hemodialysis is not performed, CrCl <30 ml/min, as well as with confirmed hyperkalemia).

Use with caution in renal failure (CrCl 30-60 ml/min).

Pediatric Use

Contraindicated in children under 12 years of age.

Geriatric Use

Should be used with caution in elderly patients.

Special Precautions

Patients with gastrointestinal diseases require regular monitoring. If ulcerative gastrointestinal lesions or gastrointestinal bleeding occur, Meloxicam should be discontinued.

Gastrointestinal ulcers, perforation, or bleeding can occur during the use of NSAIDs at any time, both in the presence of warning symptoms or a history of serious gastrointestinal complications, and in their absence. The consequences of these complications are generally more serious for the elderly.

Serious skin reactions such as exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis may develop with the use of meloxicam. Therefore, special attention should be paid to patients reporting the development of adverse events from the skin and mucous membranes, as well as hypersensitivity reactions to the drug, especially if such reactions were observed during previous courses of treatment. The development of such reactions is usually observed within the first month of treatment. If the first signs of a skin rash, changes in the mucous membranes, or other signs of hypersensitivity appear, the issue of discontinuing the use of meloxicam should be considered.

Cases of an increased risk of serious cardiovascular thrombosis, myocardial infarction, and angina attack, possibly fatal, have been described when taking NSAIDs. This risk increases with long-term use of the drug, as well as in patients with a history of the above-mentioned diseases and those predisposed to such diseases.

NSAIDs inhibit the synthesis of prostaglandins in the kidneys, which are involved in maintaining renal perfusion. The use of NSAIDs in patients with reduced renal blood flow or reduced circulating blood volume may lead to decompensation of latent renal failure. After discontinuation of NSAIDs, kidney function usually returns to baseline. Patients at greatest risk for this reaction are the elderly, patients who are dehydrated, have congestive heart failure, liver cirrhosis, nephrotic syndrome, or acute renal dysfunction, patients concurrently taking diuretics, ACE inhibitors, angiotensin II receptor antagonists, and patients who have undergone major surgical interventions leading to hypovolemia. In such patients, diuresis and renal function should be carefully monitored at the beginning of therapy.

The use of NSAIDs together with diuretics can lead to sodium, potassium, and water retention, as well as a decrease in the natriuretic effect of diuretics. As a result, in predisposed patients, signs of heart failure or arterial hypertension may worsen. Therefore, careful monitoring of the condition of such patients is necessary, as well as maintaining adequate hydration.

Renal function should be examined before starting treatment. In case of combination therapy, renal function should also be monitored.

When using meloxicam (as well as most other NSAIDs), episodic increases in serum transaminase activity or other liver function parameters are possible. In most cases, this increase was small and transient. If the detected changes are significant or do not decrease over time, Meloxicam should be discontinued and the identified laboratory changes should be monitored.

Weakened or debilitated patients may tolerate adverse events less well, so such patients should be carefully monitored.

Like other NSAIDs, Meloxicam may mask the symptoms of an underlying infectious disease.

As an agent that inhibits COX/prostaglandin synthesis, Meloxicam may affect fertility and is therefore not recommended for women having difficulty conceiving. In women undergoing examination for this reason, discontinuation of meloxicam is recommended.

In patients with mild to moderate renal failure (CrCl>25 ml/min), dose adjustment is not required.

In patients with liver cirrhosis (compensated), dose adjustment is not required.

Effect on ability to drive vehicles and operate machinery

When driving a car and working with machinery, the possibility of developing dizziness, drowsiness, visual impairment, or other disorders of the central nervous system should be taken into account. During the treatment period, patients must exercise caution when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Drug Interactions

Other inhibitors of prostaglandin synthesis, including glucocorticoids and salicylates – simultaneous administration with meloxicam increases the risk of gastrointestinal ulcers and gastrointestinal bleeding (due to the synergy of action). Simultaneous use with other NSAIDs is not recommended.

Oral anticoagulants, heparin for systemic use, thrombolytic agents – simultaneous administration with meloxicam increases the risk of bleeding. In case of simultaneous use, careful monitoring of the blood coagulation system is necessary.

Antiplatelet drugs, serotonin reuptake inhibitors – simultaneous administration with meloxicam increases the risk of bleeding due to inhibition of platelet function. In case of simultaneous use, careful monitoring of the blood coagulation system is necessary.

Lithium preparations – NSAIDs increase the level of lithium in plasma by reducing its renal excretion. Simultaneous use of meloxicam with lithium preparations is not recommended. If simultaneous use is necessary, careful monitoring of the plasma concentration of lithium is recommended throughout the course of use of lithium preparations.

Methotrexate – NSAIDs reduce the renal secretion of methotrexate, thereby increasing its plasma concentration. Concurrent use of meloxicam and methotrexate (at a dose of more than 15 mg per week) is not recommended. In case of simultaneous use, careful monitoring of renal function and blood count is necessary. Meloxicam may enhance the hematological toxicity of methotrexate, especially in patients with impaired renal function.

Diuretics – The use of NSAIDs in patients taking diuretics who are dehydrated carries a risk of acute renal failure.

Antihypertensive agents (beta-blockers, ACE inhibitors, vasodilators, diuretics). NSAIDs reduce the effect of antihypertensive agents due to inhibition of prostaglandins, which have vasodilating properties.

Angiotensin II receptor antagonists, as well as ACE inhibitors, when used concomitantly with NSAIDs, enhance the reduction in glomerular filtration, which may thereby lead to the development of acute renal failure, especially in patients with impaired renal function.

Cholestyramine, by binding Meloxicam in the gastrointestinal tract, leads to its more rapid elimination.

Pemetrexed – When meloxicam and pemetrexed are used concomitantly in patients with a CrCl from 45 to 79 ml/min, meloxicam should be discontinued 5 days before starting pemetrexed and may be resumed 2 days after the end of pemetrexed administration. If concomitant use of meloxicam and pemetrexed is necessary, patients should be closely monitored, especially for myelosuppression and gastrointestinal adverse reactions. The use of meloxicam concomitantly with pemetrexed in patients with CrCl <45 ml/min is not recommended.

NSAIDs, by affecting renal prostaglandins, may enhance the nephrotoxicity of cyclosporine.

When used concomitantly with meloxicam and drugs known to inhibit CYP2C9 and/or CYP3A4 (or are metabolized by these enzymes), such as sulfonylurea derivatives or probenecid, the possibility of pharmacokinetic interaction should be considered.

Concomitant use with oral hypoglycemic agents (e.g., sulfonylurea derivatives, nateglinide) may lead to a CYP2C9-mediated interaction, which could result in increased plasma concentrations of both the hypoglycemic agents and meloxicam. Patients taking Meloxicam concomitantly with sulfonylurea drugs or nateglinide should have their blood glucose levels carefully monitored due to the potential for hypoglycemia.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Meloxicam [Aurobindo Pharma, Ltd. (India)]
Tablets 7.5 mg: 10, 20 or 30 pcs.
Tablets 15 mg: 10, 20 or 30 pcs.

Marketing Authorization Holder

Aurobindo Pharma, Ltd. (India)

Dosage Forms

	Meloxicam	Tablets 7.5 mg: 10, 20 or 30 pcs.
		Tablets 15 mg: 10, 20 or 30 pcs.

Dosage Form, Packaging, and Composition

Tablets are round, light yellow with a slight greenish tint and a rough surface, with one side beveled from the edge to the score line, engraved with “F” and “2” on either side of the score line, and the other side is flat.

	1 tab.
Meloxicam	15 mg

Excipients: lactose monohydrate 20 mg, microcrystalline cellulose 94.8 mg, sodium citrate 18.5 mg, crospovidone 16 mg, povidone 10.5 mg, colloidal silicon dioxide 3.5 mg, magnesium stearate 1.7 mg.

10 pcs. – blister packs (1) – cardboard packs.
10 pcs. – blister packs (2) – cardboard packs.
10 pcs. – blister packs (3) – cardboard packs.

Tablets are round, light yellow with a slight greenish tint and a rough surface, with one side beveled from the edge to the score line, engraved with “F” and “1” on either side of the score line, and the other side is flat.

	1 tab.
Meloxicam	7.5 mg

Excipients: lactose monohydrate 23.5 mg, microcrystalline cellulose 102.3 mg, sodium citrate 15 mg, crospovidone 16 mg, povidone 10.5 mg, colloidal silicon dioxide 3.5 mg, magnesium stearate 1.7 mg.

10 pcs. – blister packs (1) – cardboard packs.
10 pcs. – blister packs (2) – cardboard packs.
10 pcs. – blister packs (3) – cardboard packs.

Meloxicam [Alvils, LLC (Russia)]
Solution for intramuscular injection 10 mg/ml: 1.5 ml amp. 3 pcs.

Marketing Authorization Holder

Alvils, LLC (Russia)

Manufactured By

NORTH CHINA PHARMACEUTICAL CORPORATION, Ltd. (China)

Dosage Form

Meloxicam

Solution for intramuscular injection 10 mg/ml: 1.5 ml amp. 3 pcs.

Dosage Form, Packaging, and Composition

Solution for intramuscular injection is a transparent liquid, yellow with a greenish tint.

	1 ml
Meloxicam	10 mg

Excipients: ethanol – 100 mg, propylene glycol – 66 mg, poloxamer 188 – 50 mg, macrogol 400 – 34 mg, sodium chloride – 8 mg, meglumine – 6 mg, glycine – 5 mg, water for injections – up to 1 ml.

1.5 ml – ampoules made of colorless type I glass (3) – plastic trays (1) – cardboard packs.

Meloxicam [Altayvitamins, JSC (Russia)]
Tablets 7.5 mg: 10 or 20 pcs.

Marketing Authorization Holder

Altayvitamins, JSC (Russia)

Dosage Form

Meloxicam

Tablets 7.5 mg: 10 or 20 pcs.

Dosage Form, Packaging, and Composition

Tablets	1 tab.
Meloxicam	7.5 mg

10 pcs. – blister packs (2) – cardboard packs.
10 pcs. – blister packs (1) – cardboard packs.
20 pcs. – blister packs (1) – cardboard packs.

Meloxicam [Altayvitamins, JSC (Russia)]
Tablets 15 mg: 10 or 20 pcs.

Marketing Authorization Holder

Altayvitamins, JSC (Russia)

Dosage Form

Meloxicam

Tablets 15 mg: 10 or 20 pcs.

Dosage Form, Packaging, and Composition

Tablets	1 tab.
Meloxicam	15 mg

10 pcs. – blister packs (2) – cardboard packs.
10 pcs. – blister packs (1) – cardboard packs.
20 pcs. – blister packs (1) – cardboard packs.

Meloxicam [Atoll LLC (Russia)]
Intramuscular solution 10 mg/1 ml: 1.5 ml amp. 3, 5, 6, 10, 12, or 20 pcs.

Marketing Authorization Holder

Atoll LLC (Russia)

Manufactured By

Ozon, LLC (Russia)

Dosage Form

Meloxicam

Intramuscular solution 10 mg/1 ml: 1.5 ml amp. 3, 5, 6, 10, 12, or 20 pcs.

Dosage Form, Packaging, and Composition

Solution for intramuscular injection is greenish-yellow, transparent or slightly opalescent.

	1 ml
Meloxicam	10 mg

Excipients: tetrahydrofurfuryl macrogol (glycofurol) – 100 mg, poloxamer 188 – 50 mg, meglumine – 6.25 mg, glycine – 5 mg, sodium chloride – 3 mg, 1M sodium hydroxide solution – to pH 8.2 – 8.9, water for injections – up to 1 ml.

1.5 ml – ampoules (3) – blister packs (1) – cardboard packs.
1.5 ml – ampoules (3) – blister packs (2) – cardboard packs.
1.5 ml – ampoules (3) – blister packs (4) – cardboard packs.
1.5 ml – ampoules (5) – blister packs (1) – cardboard packs.
1.5 ml – ampoules (5) – blister packs (2) – cardboard packs.
1.5 ml – ampoules (5) – blister packs (4) – cardboard packs.

Meloxicam [Biosintez, PJSC (Russia)]
Intramuscular solution 10 mg/ml: 1.5 ml amp. 3 or 5 pcs.

Marketing Authorization Holder

Biosintez, PJSC (Russia)

Dosage Form

Meloxicam

Intramuscular solution 10 mg/ml: 1.5 ml amp. 3 or 5 pcs.

Dosage Form, Packaging, and Composition

Solution for intramuscular injection is yellow with a greenish tint, transparent or slightly opalescent.

	1 amp.
Meloxicam	15 mg

Excipients: meglumine – 9.375 mg, poloxamer 188 – 75 mg, glycofurfuryl – 150 mg, sodium chloride – 4.5 mg, glycine – 7.5 mg, sodium hydroxide – 0.228 mg, water for injections – up to 1.5 ml.

1.5 ml – ampoules with a volume of 2 ml (3) – blister packs (1) – cardboard packs.
1.5 ml – ampoules with a volume of 2 ml (5) – blister packs (1) – cardboard packs.

Meloxicam [Borisov Plant Of Medical Preparations, PJSC (Republic Of Belarus)]
Tablets 7.5 mg: 20 or 30 pcs.

Marketing Authorization Holder

Borisov Plant Of Medical Preparations, PJSC (Republic Of Belarus)

Dosage Form

Meloxicam

Tablets 7.5 mg: 20 or 30 pcs.

Dosage Form, Packaging, and Composition

Tablets are yellow, round, flat-cylindrical, with a bevel.

	1 tab.
Meloxicam	7.5 mg

Excipients: microcrystalline cellulose – 9 mg, sodium citrate – 13.5 mg, anhydrous colloidal silicon dioxide – 3 mg, povidone K25 – 8.25 mg, crospovidone – 12.45 mg, magnesium stearate – 1.5 mg, lactose monohydrate – from 94.69 mg to 94.87 mg.

10 pcs. – blister packs (2) – cardboard packs.
10 pcs. – blister packs (3) – cardboard packs.

Meloxicam [Borisov Plant Of Medical Preparations, PJSC (Republic Of Belarus)]
Tablets 15 mg: 20 or 30 pcs.

Marketing Authorization Holder

Borisov Plant Of Medical Preparations, PJSC (Republic Of Belarus)

Dosage Form

Meloxicam

Tablets 15 mg: 20 or 30 pcs.

Dosage Form, Packaging, and Composition

Tablets are yellow, round, flat-cylindrical, with a bevel and a score on one side.

	1 tab.
Meloxicam	15 mg

Excipients: microcrystalline cellulose – 18 mg, sodium citrate – 27 mg, anhydrous colloidal silicon dioxide – 6 mg, povidone K25 – 16.5 mg, crospovidone – 24.9 mg, magnesium stearate – 3 mg, lactose monohydrate – from 189.38 mg to 189.74 mg.

10 pcs. – blister packs (2) – cardboard packs.
10 pcs. – blister packs (3) – cardboard packs.

Meloxicam [Bright Way, LLC (Russia)]
Tablets 7.5 mg: 6, 10, 12, 14, 15, 18, 20, 21, 24, 28, 30, 35, 36, 40, 42, 45, 48, 49, 50, 54, 56, 60, 63, 70, 75, 80, 90, 100, 105, 120, 135, 140, 150, 160, 180, or 200 pcs.
Tablets 15 mg: 6, 10, 12, 14, 15, 18, 20, 21, 24, 28, 30, 35, 36, 40, 42, 45, 48, 49, 50, 54, 56, 60, 63, 70, 75, 80, 90, 100, 105, 120, 135, 140, 150, 160, 180, or 200 pcs.

Marketing Authorization Holder

Bright Way, LLC (Russia)

Manufactured By

Velpharm, LLC (Russia)

Dosage Forms

	Meloxicam	Tablets 7.5 mg: 6, 10, 12, 14, 15, 18, 20, 21, 24, 28, 30, 35, 36, 40, 42, 45, 48, 49, 50, 54, 56, 60, 63, 70, 75, 80, 90, 100, 105, 120, 135, 140, 150, 160, 180, or 200 pcs.
		Tablets 15 mg: 6, 10, 12, 14, 15, 18, 20, 21, 24, 28, 30, 35, 36, 40, 42, 45, 48, 49, 50, 54, 56, 60, 63, 70, 75, 80, 90, 100, 105, 120, 135, 140, 150, 160, 180, or 200 pcs.

Dosage Form, Packaging, and Composition

Tablets are from light yellow to yellow with a greenish tint, round, flat-cylindrical, with a bevel; the presence of “marbling” and small inclusions is allowed.

	1 tab.
Meloxicam	7.5 mg

Excipients: lactose monohydrate (milk sugar), crospovidone (Kollidon CL, Kollidon CL-M), talc, magnesium stearate, microcrystalline cellulose 101.

6 pcs. – blister packs (1) – cardboard packs.
6 pcs. – blister packs (2) – cardboard packs.
6 pcs. – blister packs (3) – cardboard packs.
6 pcs. – blister packs (4) – cardboard packs.
6 pcs. – blister packs (5) – cardboard packs.
6 pcs. – blister packs (6) – cardboard packs.
6 pcs. – blister packs (7) – cardboard packs.
6 pcs. – blister packs (8) – cardboard packs.
6 pcs. – blister packs (9) – cardboard packs.
6 pcs. – blister packs (10) – cardboard packs.
7 pcs. – blister packs (1) – cardboard packs.
7 pcs. – blister packs (2) – cardboard packs.
7 pcs. – blister packs (3) – cardboard packs.
7 pcs. – blister packs (4) – cardboard packs.
7 pcs. – blister packs (5) – cardboard packs.
7 pcs. – blister packs (6) – cardboard packs.
7 pcs. – blister packs (7) – cardboard packs.
7 pcs. – blister packs (8) – cardboard packs.
7 pcs. – blister packs (9) – cardboard packs.
7 pcs. – blister packs (10) – cardboard packs.
10 pcs. – blister packs (1) – cardboard packs.
10 pcs. – blister packs (2) – cardboard packs.
10 pcs. – blister packs (3) – cardboard packs.
10 pcs. – blister packs (4) – cardboard packs.
10 pcs. – blister packs (5) – cardboard packs.
10 pcs. – blister packs (6) – cardboard packs.
10 pcs. – blister packs (7) – cardboard packs.
10 pcs. – blister packs (8) – cardboard packs.
10 pcs. – blister packs (9) – cardboard packs.
10 pcs. – blister packs (10) – cardboard packs.
15 pcs. – blister packs (1) – cardboard packs.
15 pcs. – blister packs (2) – cardboard packs.
15 pcs. – blister packs (3) – cardboard packs.
15 pcs. – blister packs (4) – cardboard packs.
15 pcs. – blister packs (5) – cardboard packs.
15 pcs. – blister packs (6) – cardboard packs.
15 pcs. – blister packs (7) – cardboard packs.
15 pcs. – blister packs (8) – cardboard packs.
15 pcs. – blister packs (9) – cardboard packs.
15 pcs. – blister packs (10) – cardboard packs.
20 pcs. – blister packs (1) – cardboard packs.
20 pcs. – blister packs (2) – cardboard packs.
20 pcs. – blister packs (3) – cardboard packs.
20 pcs. – blister packs (4) – cardboard packs.
20 pcs. – blister packs (5) – cardboard packs.
20 pcs. – blister packs (6) – cardboard packs.
20 pcs. – blister packs (7) – cardboard packs.
20 pcs. – blister packs (8) – cardboard packs.
20 pcs. – blister packs (9) – cardboard packs.
20 pcs. – blister packs (10) – cardboard packs.
10 pcs. – jars – cardboard packs.
20 pcs. – jars – cardboard packs.
30 pcs. – jars – cardboard packs.
40 pcs. – jars – cardboard packs.
50 pcs. – jars – cardboard packs.
60 pcs. – jars – cardboard packs.
70 pcs. – jars – cardboard packs.
80 pcs. – jars – cardboard packs.
90 pcs. – jars – cardboard packs.
100 pcs. – jars – cardboard packs.

Tablets are from light yellow to yellow with a greenish tint, round, flat-cylindrical, with a bevel and a score; the presence of “marbling” and small inclusions is allowed.

	1 tab.
Meloxicam	15 mg

Excipients: lactose monohydrate (milk sugar), crospovidone (Kollidon CL, Kollidon CL-M), talc, magnesium stearate, microcrystalline cellulose 101.

6 pcs. – contour cell packs (1) – cardboard packs.
6 pcs. – contour cell packs (2) – cardboard packs.
6 pcs. – contour cell packs (3) – cardboard packs.
6 pcs. – contour cell packs (4) – cardboard packs.
6 pcs. – contour cell packs (5) – cardboard packs.
6 pcs. – contour cell packs (6) – cardboard packs.
6 pcs. – contour cell packs (7) – cardboard packs.
6 pcs. – contour cell packs (8) – cardboard packs.
6 pcs. – contour cell packs (9) – cardboard packs.
6 pcs. – contour cell packs (10) – cardboard packs.
7 pcs. – contour cell packs (1) – cardboard packs.
7 pcs. – contour cell packs (2) – cardboard packs.
7 pcs. – contour cell packs (3) – cardboard packs.
7 pcs. – contour cell packs (4) – cardboard packs.
7 pcs. – contour cell packs (5) – cardboard packs.
7 pcs. – contour cell packs (6) – cardboard packs.
7 pcs. – contour cell packs (7) – cardboard packs.
7 pcs. – contour cell packs (8) – cardboard packs.
7 pcs. – contour cell packs (9) – cardboard packs.
7 pcs. – contour cell packs (10) – cardboard packs.
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
10 pcs. – contour cell packs (7) – cardboard packs.
10 pcs. – contour cell packs (8) – cardboard packs.
10 pcs. – contour cell packs (9) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
15 pcs. – contour cell packs (1) – cardboard packs.
15 pcs. – contour cell packs (2) – cardboard packs.
15 pcs. – contour cell packs (3) – cardboard packs.
15 pcs. – contour cell packs (4) – cardboard packs.
15 pcs. – contour cell packs (5) – cardboard packs.
15 pcs. – contour cell packs (6) – cardboard packs.
15 pcs. – contour cell packs (7) – cardboard packs.
15 pcs. – contour cell packs (8) – cardboard packs.
15 pcs. – contour cell packs (9) – cardboard packs.
15 pcs. – contour cell packs (10) – cardboard packs.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (2) – cardboard packs.
20 pcs. – contour cell packs (3) – cardboard packs.
20 pcs. – contour cell packs (4) – cardboard packs.
20 pcs. – contour cell packs (5) – cardboard packs.
20 pcs. – contour cell packs (6) – cardboard packs.
20 pcs. – contour cell packs (7) – cardboard packs.
20 pcs. – contour cell packs (8) – cardboard packs.
20 pcs. – contour cell packs (9) – cardboard packs.
20 pcs. – contour cell packs (10) – cardboard packs.
10 pcs. – jars – cardboard packs.
20 pcs. – jars – cardboard packs.
30 pcs. – jars – cardboard packs.
40 pcs. – jars – cardboard packs.
50 pcs. – jars – cardboard packs.
60 pcs. – jars – cardboard packs.
70 pcs. – jars – cardboard packs.
80 pcs. – jars – cardboard packs.
90 pcs. – jars – cardboard packs.
100 pcs. – jars – cardboard packs.

Meloxicam [Bright Way, LLC (Russia)]
Solution for intramuscular administration 10 mg/1 ml: 1.5 ml amp. 3, 5, 6 or 10 pcs.

Marketing Authorization Holder

Bright Way, LLC (Russia)

Manufactured By

Velpharm, LLC (Russia)

Dosage Form

Meloxicam

Solution for intramuscular administration 10 mg/1 ml: 1.5 ml amp. 3, 5, 6 or 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intramuscular administration yellow with a greenish tint, transparent or slightly opalescent.

	1 ml
Meloxicam	10 mg

Excipients: meglumine, tetraglycol (glycofurfural, glycofurol), poloxamer 188, sodium chloride, glycine, sodium hydroxide solution 1M, water for injections.

1.5 ml – neutral glass ampoules (3) – contour cell packs (1) – cardboard packs.
1.5 ml – neutral glass ampoules (3) – contour cell packs (2) – cardboard packs.
1.5 ml – neutral glass ampoules (5) – contour cell packs (1) – cardboard packs.
1.5 ml – neutral glass ampoules (5) – contour cell packs (2) – cardboard packs.

Meloxicam [B-PHARM, LLC (Russia)]
Intramuscular solution 10 mg/1 ml: 1.5 ml amp. 3, 5, or 10 pcs.

Marketing Authorization Holder

B-PHARM, LLC (Russia)

Manufactured By

Kursk Biopharmaceutical Plant – Firm “Biok”, FKP (Russia)

B-PHARM, LLC (Russia)

Dosage Form

Meloxicam

Intramuscular solution 10 mg/1 ml: 1.5 ml amp. 3, 5, or 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intramuscular administration transparent or slightly opalescent, yellow with a greenish tint.

	1 ml
Meloxicam	10 mg

Excipients: meglumine – 6.25 mg, tetrahydrofurfuryl macrogol – 100 mg, poloxamer 188 – 50 mg, sodium chloride – 3 mg, glycine – 5 mg, sodium hydroxide solution 1M – to pH 8.2-8.9, water for injections – to 1 ml.

1.5 ml – ampoules (3) – contour cell packs (1) – cardboard packs.
1.5 ml – ampoules (5) – contour cell packs (1) – cardboard packs.
1.5 ml – ampoules (5) – contour cell packs (2) – cardboard packs.

Meloxicam [Dalkhimpharm, JSC (Russia)]
Solution for intramuscular administration 10 mg/1 ml: 1.5 ml amp. 3, 5, 6 or 10 pcs.

Marketing Authorization Holder

Dalkhimpharm, JSC (Russia)

Dosage Form

Meloxicam

Solution for intramuscular administration 10 mg/1 ml: 1.5 ml amp. 3, 5, 6 or 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intramuscular administration from yellow to yellow with a greenish tint.

	1 ml
Meloxicam	10 mg

Excipients: meglumine – 6.25 mg, glycofurol (tetrahydrofurfuryl alcohol) – 100 mg, poloxamer 188 – 50 mg, sodium chloride – 3 mg, glycine – 5 mg, sodium hydroxide solution 1M – pH 8.4-8.8, water for injections – to 1 ml.

Meloxicam [Dalkhimpharm, JSC (Russia)]
Rectal suppositories 7.5 mg: 5 or 10 pcs.

Marketing Authorization Holder

Dalkhimpharm, JSC (Russia)

Dosage Form

Meloxicam

Rectal suppositories 7.5 mg: 5 or 10 pcs.

Dosage Form, Packaging, and Composition

Rectal suppositories from light yellow with a greenish tint to greenish-yellow, torpedo-shaped.

	1 supp.
Meloxicam	7.5 mg

Excipients: hard fats – sufficient quantity to obtain a suppository weighing 1.25 mg.

5 pcs. – contour cell packs (1) – cardboard packs.
5 pcs. – contour cell packs (2) – cardboard packs.

Meloxicam [Dalkhimpharm, JSC (Russia)]
Rectal suppositories 15 mg: 5 or 10 pcs.

Marketing Authorization Holder

Dalkhimpharm, JSC (Russia)

Dosage Form

Meloxicam

Rectal suppositories 15 mg: 5 or 10 pcs.

Dosage Form, Packaging, and Composition

Rectal suppositories from light yellow with a greenish tint to greenish-yellow, torpedo-shaped.

	1 supp.
Meloxicam	15 mg

Excipients: hard fats – sufficient quantity to obtain a suppository weighing 1.25 mg.

5 pcs. – contour cell packs (1) – cardboard packs.
5 pcs. – contour cell packs (2) – cardboard packs.

Meloxicam [Canonpharma Production, CJS (Russia)]
Tablets 7.5 mg: 10, 20, or 30 pcs.
Tablets 15 mg: 10, 20 or 30 pcs.

Marketing Authorization Holder

Canonpharma Production, CJS (Russia)

Dosage Forms

	Meloxicam	Tablets 7.5 mg: 10, 20, or 30 pcs.
		Tablets 15 mg: 10, 20 or 30 pcs.

Dosage Form, Packaging, and Composition

Tablets light yellow with a greenish tint, flat-cylindrical, with a bevel.

	1 tab.
Meloxicam	15 mg

Excipients: potato starch 33.4 mg, colloidal silicon dioxide (aerosil) 4.4 mg, lactose monohydrate 165 mg, magnesium stearate 2.2 mg.

10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.

Tablets light yellow with a greenish tint, flat-cylindrical, with a bevel.

	1 tab.
Meloxicam	7.5 mg

Excipients: potato starch 16.7 mg, colloidal silicon dioxide 2.2 mg, lactose monohydrate 82.5 mg, magnesium stearate 1.1 mg.

10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.

Meloxicam [Canonpharma Production, CJS (Russia)]
Intramuscular solution 15 mg/1.5 ml: amp. 3, 5, 10, or 525 pcs.

Marketing Authorization Holder

Canonpharma Production, CJS (Russia)

Manufactured By

State Institute of Medical and Biological Problems, FSUE (Russia)

Dosage Form

Meloxicam

Intramuscular solution 15 mg/1.5 ml: amp. 3, 5, 10, or 525 pcs.

Dosage Form, Packaging, and Composition

Solution for intramuscular administration	1 ml	1 amp.
Meloxicam	10 mg	15 mg

1.5 ml – dark glass ampoules (3) – contour cell packs (1) – cardboard packs.
1.5 ml – dark glass ampoules (5) – contour cell packs (1) – cardboard packs.
1.5 ml – dark glass ampoules (10) – contour cell packs (1) – cardboard packs.
1.5 ml – dark glass ampoules (10) – contour cell packs (2) – cardboard packs.
1.5 ml – dark glass ampoules (525) – cardboard boxes – cardboard packs.

Meloxicam [Medisorb, JSC (Russia)]
Tablets 7.5 mg: 10, 20, 30, 50 or 100 pcs.
Tablets 15 mg: 10, 20, 30, 50 or 100 pcs.

Marketing Authorization Holder

Medisorb, JSC (Russia)

Dosage Forms

	Meloxicam	Tablets 7.5 mg: 10, 20, 30, 50 or 100 pcs.
		Tablets 15 mg: 10, 20, 30, 50 or 100 pcs.

Dosage Form, Packaging, and Composition

Tablets light yellow, round, flat-cylindrical, with a bevel.

	1 tab.
Meloxicam	7.5 mg

Excipients: lactose monohydrate (milk sugar) – 80.5 mg, povidone (polyvinylpyrrolidone) – 4 mg, potato starch – 7 mg, magnesium stearate – 1 mg.

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
20 pcs. – polymer jars (1) – cardboard packs.
30 pcs. – polymer jars (1) – cardboard packs.
50 pcs. – polymer jars (1) – cardboard packs.
100 pcs. – polymer jars (1) – cardboard packs.

Tablets light yellow, round, flat-cylindrical, with a bevel.

	1 tab.
Meloxicam	15 mg

Excipients: lactose monohydrate (milk sugar) – 161 mg, povidone (polyvinylpyrrolidone) – 8 mg, potato starch – 14 mg, magnesium stearate – 2 mg.

Meloxicam [Mosfarm LLC (Russia)]
Intramuscular solution 10 mg/1 ml: 1.5 ml amp. 3, 5, or 10 pcs.

Marketing Authorization Holder

Mosfarm LLC (Russia)

Dosage Form

Meloxicam

Intramuscular solution 10 mg/1 ml: 1.5 ml amp. 3, 5, or 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intramuscular administration transparent, yellow with a greenish tint.

	1 ml
Meloxicam	10 mg

Meloxicam [PharmVILAR NPO, LLC (Russia)]
Tablets 7.5 mg: 10, 20, 30, 40, 50, 60, or 120 pcs.
Tablets 15 mg: 10, 20, 30, 40, 50, 60, or 120 pcs.

Marketing Authorization Holder

PharmVILAR NPO, LLC (Russia)

Dosage Forms

	Meloxicam	Tablets 7.5 mg: 10, 20, 30, 40, 50, 60, or 120 pcs.
		Tablets 15 mg: 10, 20, 30, 40, 50, 60, or 120 pcs.

Dosage Form, Packaging, and Composition

Tablets from light yellow to yellow, round, flat-cylindrical, with a bevel; a faint greenish tint is possible, the presence of lighter and darker inclusions is allowed.

	1 tab.
Meloxicam	7.5 mg

Excipients: lactose monohydrate – 67 mg, microcrystalline cellulose type 101 or 102 – 15 mg, sodium citrate dihydrate – 4 mg, croscarmellose sodium – 2 mg, povidone K30 – 3.5 mg, magnesium stearate – 1 mg.

Tablets from light yellow to yellow, round, flat-cylindrical, with a bevel, with a score on one side; a faint greenish tint is possible, the presence of lighter and darker inclusions is allowed.

	1 tab.
Meloxicam	15 mg

Excipients: lactose monohydrate – 134 mg, microcrystalline cellulose type 101 or 102 – 30 mg, sodium citrate dihydrate – 8 mg, croscarmellose sodium – 4 mg, povidone K30 – 7 mg, magnesium stearate – 2 mg.

Meloxicam [Ozon, LLC (Russia)]
Tablets 7.5 mg: 10, 20, 30, 40, 50, 60, 80, 90, 100, 120, 150, 200, or 300 pcs.

Marketing Authorization Holder

Ozon, LLC (Russia)

Dosage Form

Meloxicam

Tablets 7.5 mg: 10, 20, 30, 40, 50, 60, 80, 90, 100, 120, 150, 200, or 300 pcs.

Dosage Form, Packaging, and Composition

Tablets	1 tab.
Meloxicam	7.5 mg

10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
20 pcs. – contour cell packs (10) – cardboard packs.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (3) – cardboard packs.
20 pcs. – contour cell packs (4) – cardboard packs.
20 pcs. – contour cell packs (5) – cardboard packs.
30 pcs. – contour cell packs (1) – cardboard packs.
30 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – contour cell packs (3) – cardboard packs.
30 pcs. – contour cell packs (4) – cardboard packs.
30 pcs. – contour cell packs (5) – cardboard packs.
30 pcs. – contour cell packs (10) – cardboard packs.
40 pcs. – contour cell packs (1) – cardboard packs.
50 pcs. – contour cell packs (1) – cardboard packs.
50 pcs. – contour cell packs (100) – cardboard packs.

Meloxicam [Ozon, LLC (Russia)]
Tablets 15 mg: 10, 20, 30, 40, 50, 60, 80, 90, 100, 120, 150, 200, or 300 pcs.

Marketing Authorization Holder

Ozon, LLC (Russia)

Dosage Form

Meloxicam

Tablets 15 mg: 10, 20, 30, 40, 50, 60, 80, 90, 100, 120, 150, 200, or 300 pcs.

Dosage Form, Packaging, and Composition

Tablets	1 tab.
Meloxicam	15 mg

10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (2) – cardboard packs.
20 pcs. – contour cell packs (3) – cardboard packs.
20 pcs. – contour cell packs (4) – cardboard packs.
20 pcs. – contour cell packs (5) – cardboard packs.
20 pcs. – contour cell packs (10) – cardboard packs.
30 pcs. – contour cell packs (1) – cardboard packs.
30 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – contour cell packs (3) – cardboard packs.
30 pcs. – contour cell packs (4) – cardboard packs.
30 pcs. – contour cell packs (5) – cardboard packs.
30 pcs. – contour cell packs (10) – cardboard packs.
40 pcs. – contour cell packs (1) – cardboard packs.
50 pcs. – contour cell packs (1) – cardboard packs.

Meloxicam [Promomed Rus LLC (Russia)]
Intramuscular solution 10 mg/ml: 1.5 ml amp. 5 or 10 pcs.

Marketing Authorization Holder

Promomed Rus LLC (Russia)

Manufactured By

Biokhimik, JSC (Russia)

Dosage Form

Meloxicam

Intramuscular solution 10 mg/ml: 1.5 ml amp. 5 or 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intramuscular injection greenish-yellow, transparent.

	1 ml
Meloxicam	10 mg

Excipients: meglumine – 6.25 mg, glycofurol – 100 mg, poloxamer 188 – 50 mg, sodium chloride – 3 mg, glycine – 5 mg, sodium hydroxide 1M solution – to pH 8.2-8.9, water for injection – to 1 ml.

1.5 ml – neutral glass ampoules (5) – contour cell packs (1) – cardboard packs.
1.5 ml – neutral glass ampoules (5) – contour cell packs (2) – cardboard packs.
1.5 ml – neutral glass ampoules (10) – cardboard boxes.

Meloxicam [Rif LLC (Russia)]
Gel for external use 1%: tubes 30 g or 50 g

Marketing Authorization Holder

Rif LLC (Russia)

Manufactured By

Ozon, LLC (Russia)

Dosage Form

Meloxicam

Gel for external use 1%: tubes 30 g or 50 g

Dosage Form, Packaging, and Composition

Gel for external use transparent, yellow in color, with a characteristic odor.

	100 g
Meloxicam	1 g

Excipients: dimethyl sulfoxide, ethanol 95%, trometamol, carbomer, orange flower oil, lavender oil, purified water.

30 g – aluminum tubes (1) – cardboard packs.
50 g – aluminum tubes (1) – cardboard packs.

Meloxicam [Sintez PJSC (Russia)]
Intramuscular solution 10 mg/ml: 1.5 ml amp. 3, 5, 6, or 10 pcs.

Marketing Authorization Holder

Sintez PJSC (Russia)

Dosage Form

Meloxicam

Intramuscular solution 10 mg/ml: 1.5 ml amp. 3, 5, 6, or 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intramuscular injection as a transparent liquid, yellow with a greenish tint.

	1 ml
Meloxicam	10 mg

Excipients: sodium chloride, glycine, glycofurol, poloxamer 188, meglumine, sodium hydroxide, water for injection.

1.5 ml – ampoules (3) – cardboard pack.
1.5 ml – ampoules (5) – cardboard pack.
1.5 ml – ampoules (6) – cardboard pack.
1.5 ml – ampoules (10) – cardboard pack.

Meloxicam [Sintez PJSC (Russia)]
Tablets 7.5 mg: 10, 20, 30, 50 or 100 pcs.
Tablets 15 mg: 10, 20, 30, 50 or 100 pcs.

Marketing Authorization Holder

Sintez PJSC (Russia)

Dosage Forms

	Meloxicam	Tablets 7.5 mg: 10, 20, 30, 50 or 100 pcs.
		Tablets 15 mg: 10, 20, 30, 50 or 100 pcs.

Dosage Form, Packaging, and Composition

Tablets from light yellow to light yellow with a greenish tint, round, flat-cylindrical, with a bevel, without a score; the presence of “marbling” is allowed on the surface, the surface of the tablets may be rough.

	1 tab.
Meloxicam	7.5 mg

Excipients: microcrystalline cellulose (type 12), lactose monohydrate, croscarmellose sodium, talc, colloidal silicon dioxide (aerosil), magnesium stearate.

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – jars (1) – cardboard packs.
20 pcs. – jars (1) – cardboard packs.
30 pcs. – jars (1) – cardboard packs.
50 pcs. – jars (1) – cardboard packs.
100 pcs. – jars (1) – cardboard packs.

Tablets from light yellow to light yellow with a greenish tint, round, flat-cylindrical, with a bevel and a score; the presence of “marbling” is allowed on the surface, the surface of the tablets may be rough.

	1 tab.
Meloxicam	15 mg

Excipients: microcrystalline cellulose (type 12), lactose monohydrate, croscarmellose sodium, talc, colloidal silicon dioxide (aerosil), magnesium stearate.

Meloxicam [Slavic Pharmacy, LLC (Russia)]
Intramuscular solution 10 mg/ml: 1.5 ml amp. 3 or 5 pcs.

Marketing Authorization Holder

Slavic Pharmacy, LLC (Russia)

Dosage Form

Meloxicam

Intramuscular solution 10 mg/ml: 1.5 ml amp. 3 or 5 pcs.

Dosage Form, Packaging, and Composition

Solution for intramuscular injection as a transparent liquid from yellow to yellow with a greenish tint.

	1 ml
Meloxicam	10 mg

Excipients: glycine – 5 mg, propylene glycol – 64 mg, povidone K17 – 60 mg, meglumine – 6.4 mg, macrogol 400 – 60 mg, sodium hydroxide 1M solution – to pH 8.8, water for injection – to 1 ml.

1.5 ml – ampoules (3) – cardboard pack.
1.5 ml – ampoules (5) – cardboard pack.

Meloxicam [Pharmstandard-UfaVITA OJSC (Russia)]
Intramuscular solution 10 mg/1 ml: 1.5 ml amp. 3, 5, or 10 pcs.

Marketing Authorization Holder

Pharmstandard-UfaVITA OJSC (Russia)

Dosage Form

Meloxicam

Intramuscular solution 10 mg/1 ml: 1.5 ml amp. 3, 5, or 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intramuscular injection from yellow to yellow with a greenish tint, transparent.

	1 ml	1 amp.
Meloxicam	10 mg	15 mg

Excipients: meglumine, glycofurol, poloxamer 188, sodium chloride, glycine, sodium hydroxide, water for injection.

Meloxicam [Pharmstandard-UfaVITA OJSC (Russia)]
Tablets 7.5 mg: 10, 15, 20, 30, 40, 45, 60, 75, or 100 pcs.
Tablets 15 mg: 10, 15, 20, 30, 40, 45, 60, 75, or 100 pcs.

Marketing Authorization Holder

Pharmstandard-UfaVITA OJSC (Russia)

Manufactured By

Pharmstandard-Lexredstva OJSC (Russia)

Dosage Forms

	Meloxicam	Tablets 7.5 mg: 10, 15, 20, 30, 40, 45, 60, 75, or 100 pcs.
		Tablets 15 mg: 10, 15, 20, 30, 40, 45, 60, 75, or 100 pcs.

Dosage Form, Packaging, and Composition

Tablets from light yellow to yellow, round, flat-cylindrical, with a bevel and a score on one side.

	1 tab.
Meloxicam	7.5 mg

Excipients: sodium citrate dihydrate, lactose monohydrate, microcrystalline cellulose 200, povidone K25, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate.

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
15 pcs. – contour cell packs (1) – cardboard packs.
15 pcs. – contour cell packs (2) – cardboard packs.
15 pcs. – contour cell packs (3) – cardboard packs.
15 pcs. – contour cell packs (5) – cardboard packs.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (2) – cardboard packs.
20 pcs. – contour cell packs (3) – cardboard packs.
20 pcs. – contour cell packs (5) – cardboard packs.

Tablets from light yellow to yellow, round, flat-cylindrical, with a bevel and a score on one side.

	1 tab.
Meloxicam	15 mg

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
15 pcs. – contour cell packs (1) – cardboard packs.
15 pcs. – contour cell packs (2) – cardboard packs.
15 pcs. – contour cell packs (3) – cardboard packs.
15 pcs. – contour cell packs (5) – cardboard packs.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (2) – cardboard packs.
20 pcs. – contour cell packs (3) – cardboard packs.
20 pcs. – contour cell packs (5) – cardboard packs.

Meloxicam [Elius, LLC (Russia)]
Tablets 7.5 mg: 10, 20, 30, or 60 pcs.
Tablets 15 mg: 10, 20, 30, or 60 pcs.

Marketing Authorization Holder

Elius, LLC (Russia)

Manufactured By

Vertex, JSC (Russia)

Dosage Forms

	Meloxicam	Tablets 7.5 mg: 10, 20, 30, or 60 pcs.
		Tablets 15 mg: 10, 20, 30, or 60 pcs.

Dosage Form, Packaging, and Composition

Tablets from light yellow to yellow, flat-cylindrical, round, with a bevel; the presence of marbling and small inclusions is allowed.

	1 tab.
Meloxicam	7.5 mg

Excipients: lactose monohydrate – 88 mg, microcrystalline cellulose type 101 – 62.4 mg, sodium citrate dihydrate – 7.5 mg, sodium starch glycolate – 7.2 mg, povidone K-30 – 3.6 mg, colloidal silicon dioxide – 2 mg, calcium stearate – 1.8 mg.

Meloxicam [Ellara, LLC (Russia)]
Intramuscular solution 10 mg/ml: 1.5 ml amp. 3, 5, 6, or 10 pcs.

Marketing Authorization Holder

Ellara, LLC (Russia)

Dosage Form

Meloxicam

Intramuscular solution 10 mg/ml: 1.5 ml amp. 3, 5, 6, or 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intramuscular injection transparent or with slight opalescence, yellow or greenish-yellow in color.

	1 ml
Meloxicam	10 mg

Excipients: meglumine – 6.25 mg, glycofurol (glycofurol, polyethylene glycol ether of tetrahydrofurfuryl alcohol, tetraglycol) – 100 mg, poloxamer 188 – 50 mg, sodium chloride – 3 mg, glycerol (glycerin) – 5 mg, sodium hydroxide 1M solution – to pH 8.0-9.0, water for injection – to 1 ml.

1.5 ml – ampoules (3) – contour cell packaging (1) – cardboard packs.
1.5 ml – ampoules (3) – contour cell packaging (2) – cardboard packs.
1.5 ml – ampoules (5) – contour cell packaging (1) – cardboard packs.
1.5 ml – ampoules (5) – contour cell packaging (2) – cardboard packs.
1.5 ml – ampoules (3) – cardboard packs.
1.5 ml – ampoules (5) – cardboard packs.
1.5 ml – ampoules (6) – cardboard packs.
1.5 ml – ampoules (10) – cardboard packs.

Meloxicam bufus [Obnovlenie Pfc, JSC (Russia)]
Intramuscular solution 10 mg/ml: 1.5 ml amp. 3 or 5 pcs.

Marketing Authorization Holder

Obnovlenie Pfc, JSC (Russia)

Dosage Form

Meloxicam bufus

Intramuscular solution 10 mg/ml: 1.5 ml amp. 3 or 5 pcs.

Dosage Form, Packaging, and Composition

Solution for intramuscular administration as a clear yellow or greenish-yellow liquid.

	1 ml
Meloxicam	10 mg

Excipients: glycofurol (tetraglycol) – 100 mg, poloxamer 188 – 50 mg, meglumine – 6.25 mg, glycine – 5 mg, sodium chloride – 3 mg, sodium hydroxide – 0.152 mg, water for injections – up to 1 ml.

1.5 ml – ampoules (3) – cardboard packs.
1.5 ml – ampoules (5) – cardboard packs.

Meloxicam DS [Dominanta-Service, JSC (Russia)]
Solution for intramuscular injection 15 mg/1.5 ml: amp. 3 pcs.

Marketing Authorization Holder

Dominanta-Service, JSC (Russia)

Manufactured By

Vetprom, AD (Bulgaria)

Dosage Form

Meloxicam DS

Solution for intramuscular injection 15 mg/1.5 ml: amp. 3 pcs.

Dosage Form, Packaging, and Composition

Solution for intramuscular administration	1 ml	1 amp.
Meloxicam	10 mg	15 mg

1.5 ml – ampoules (3) – contour plastic packaging (1) – cardboard packs.

Meloxicam DS [Dominanta-Service, JSC (Russia)]
Tablets 7.5 mg: 10 or 20 pcs.

Marketing Authorization Holder

Dominanta-Service, JSC (Russia)

Manufactured By

Mekophar Chemical-Pharmaceutical, Joint Stock Company (Vietnam)

Dosage Form

Meloxicam DS

Tablets 7.5 mg: 10 or 20 pcs.

Dosage Form, Packaging, and Composition

Tablets	1 tab.
Meloxicam	7.5 mg

10 pcs. – contour cell packaging (1) – cardboard packs.
10 pcs. – contour cell packaging (2) – cardboard packs.

Meloxicam DS [Dominanta-Service, JSC (Russia)]
Tablets 10 mg: 10 or 20 pcs.

Marketing Authorization Holder

Dominanta-Service, JSC (Russia)

Manufactured By

Mekophar Chemical-Pharmaceutical, Joint Stock Company (Vietnam)

Dosage Form

Meloxicam DS

Tablets 10 mg: 10 or 20 pcs.

Dosage Form, Packaging, and Composition

Tablets	1 tab.
Meloxicam	10 mg

10 pcs. – contour cell packaging (1) – cardboard packs.
10 pcs. – contour cell packaging (2) – cardboard packs.

Meloxicam Medisorb [Medisorb, JSC (Russia)]
Tablets 7.5 mg: 7, 10, 14, 20, 21, 28, 30, 35, 40, 42, 49, 50, 56, 60, 63, 70, 80, 84, 90, 98, 100, 112, 126, or 140 pcs.
Tablets 15 mg: 7, 10, 14, 20, 21, 28, 30, 35, 40, 42, 49, 50, 56, 60, 63, 70, 80, 84, 90, 98, 100, 112, 126, or 140 pcs.

Marketing Authorization Holder

Medisorb, JSC (Russia)

Dosage Forms

	Meloxicam Medisorb	Tablets 7.5 mg: 7, 10, 14, 20, 21, 28, 30, 35, 40, 42, 49, 50, 56, 60, 63, 70, 80, 84, 90, 98, 100, 112, 126, or 140 pcs.
		Tablets 15 mg: 7, 10, 14, 20, 21, 28, 30, 35, 40, 42, 49, 50, 56, 60, 63, 70, 80, 84, 90, 98, 100, 112, 126, or 140 pcs.

Dosage Form, Packaging, and Composition

Tablets light yellow, round, flat-cylindrical, with a bevel.

	1 tab.
Meloxicam	7.5 mg

Excipients: lactose monohydrate, povidone K30 (medium molecular weight polyvinylpyrrolidone), potato starch, magnesium stearate.

7 pcs. – contour cell packaging (1, 2, 3, 4, 5, 6, 7, 8, 9, 10) – cardboard packs.
10 pcs. – contour cell packaging (1, 2, 3, 4, 5, 6, 7, 8, 9, 10) – cardboard packs.
14 pcs. – contour cell packaging (1, 2, 3, 4, 5, 6, 7, 8, 9, 10) – cardboard packs.
14 pcs. – polymer jars (1) – cardboard packs.
28 pcs. – polymer jars (1) – cardboard packs.
30 pcs. – polymer jars (1) – cardboard packs.
50 pcs. – polymer jars (1) – cardboard packs.
56 pcs. – polymer jars (1) – cardboard packs.
60 pcs. – polymer jars (1) – cardboard packs.
90 pcs. – polymer jars (1) – cardboard packs.
100 pcs. – polymer jars (1) – cardboard packs.
112 pcs. – polymer jars (1) – cardboard packs.
120 pcs. – polymer jars (1) – cardboard packs.

Tablets light yellow, round, flat-cylindrical, with a bevel.

	1 tab.
Meloxicam	15 mg

Excipients: lactose monohydrate, povidone K30 (medium molecular weight polyvinylpyrrolidone), potato starch, magnesium stearate.

Meloxicam Reneval [PFKO-1, LLC (Russia)]
Tablets 7.5 mg: 10, 15, 20, 30, 40, 50, or 60 pcs.
Tablets 15 mg: 10, 15, 20, 30, 40, 50, or 60 pcs.

Marketing Authorization Holder

PFKO-1, LLC (Russia)

Manufactured By

Obnovlenie Pfc, JSC (Russia)

Dosage Forms

	Meloxicam Reneval	Tablets 7.5 mg: 10, 15, 20, 30, 40, 50, or 60 pcs.
		Tablets 15 mg: 10, 15, 20, 30, 40, 50, or 60 pcs.

Dosage Form, Packaging, and Composition

Tablets round, flat-cylindrical, light yellow or yellow in color, with a bevel and a score line; marbling is allowed.

	1 tab.
Meloxicam	7.5 mg

Excipients: microcrystalline cellulose PH101, sodium carboxymethyl starch, povidone K30, magnesium stearate.

10 pcs. – contour cell packaging (1) – cardboard packs with an insert.
10 pcs. – contour cell packaging (2) – cardboard packs with an insert.
10 pcs. – contour cell packaging (3) – cardboard packs with an insert.
10 pcs. – contour cell packaging (4) – cardboard packs with an insert.
10 pcs. – contour cell packaging (5) – cardboard packs with an insert.
10 pcs. – contour cell packaging (6) – cardboard packs with an insert.
15 pcs. – contour cell packaging (1) – cardboard packs with an insert.
15 pcs. – contour cell packaging (2) – cardboard packs with an insert.
15 pcs. – contour cell packaging (4) – cardboard packs with an insert.

Tablets round, flat-cylindrical, light yellow or yellow in color, with a bevel and a score line; marbling is allowed.

	1 tab.
Meloxicam	15 mg

Excipients: microcrystalline cellulose PH101, sodium carboxymethyl starch, povidone K30, magnesium stearate.

Meloxicam Velpharm [Elzapharm, LLC (Russia)]
Tablets 7.5 mg: 6, 7, 10, 12, 14, 15, 18, 20, 21, 24, 28, 30, 35, 36, 40, 42, 45, 48, 49, 50, 54, 56, 60, 63, 70, 75, 80, 90, 100, 105, 120, 135, 140, 150, 160, 180, 200, 210, 240, 270, or 300 pcs.
Tablets 15 mg: 6, 7, 10, 12, 14, 15, 18, 20, 21, 24, 28, 30, 35, 36, 40, 42, 45, 48, 49, 50, 54, 56, 60, 63, 70, 75, 80, 90, 100, 105, 120, 135, 140, 150, 160, 180, 200, 210, 240, 270, or 300 pcs.

Marketing Authorization Holder

Elzapharm, LLC (Russia)

Manufactured By

Velpharm, LLC (Russia)

Marbiopharm, JSC (Russia)

Uralbiopharm, JSC (Russia)

Dosage Forms

	Meloxicam Velpharm	Tablets 7.5 mg: 6, 7, 10, 12, 14, 15, 18, 20, 21, 24, 28, 30, 35, 36, 40, 42, 45, 48, 49, 50, 54, 56, 60, 63, 70, 75, 80, 90, 100, 105, 120, 135, 140, 150, 160, 180, 200, 210, 240, 270, or 300 pcs.
		Tablets 15 mg: 6, 7, 10, 12, 14, 15, 18, 20, 21, 24, 28, 30, 35, 36, 40, 42, 45, 48, 49, 50, 54, 56, 60, 63, 70, 75, 80, 90, 100, 105, 120, 135, 140, 150, 160, 180, 200, 210, 240, 270, or 300 pcs.

Dosage Form, Packaging, and Composition

Tablets from light yellow to yellow with a greenish tint, round, flat-cylindrical, with a bevel; the presence of “marbling” and small inclusions is allowed.

	1 tab.
Meloxicam	7.5 mg

Excipients: lactose monohydrate (milk sugar), crospovidone (kollidon CL, kollidon CL-M), talc, magnesium stearate, microcrystalline cellulose (101).

6 pcs. – contour cell packaging (1) – cardboard packs.
6 pcs. – contour cell packaging (2) – cardboard packs.
6 pcs. – contour cell packaging (3) – cardboard packs.
6 pcs. – contour cell packaging (4) – cardboard packs.
6 pcs. – contour cell packaging (5) – cardboard packs.
6 pcs. – contour cell packaging (6) – cardboard packs.
6 pcs. – contour cell packaging (7) – cardboard packs.
6 pcs. – contour cell packaging (8) – cardboard packs.
6 pcs. – contour cell packaging (9) – cardboard packs.
6 pcs. – contour cell packaging (10) – cardboard packs.
7 pcs. – contour cell packaging (1) – cardboard packs.
7 pcs. – contour cell packaging (2) – cardboard packs.
7 pcs. – contour cell packaging (3) – cardboard packs.
7 pcs. – contour cell packaging (4) – cardboard packs.
7 pcs. – contour cell packaging (5) – cardboard packs.
7 pcs. – contour cell packaging (6) – cardboard packs.
7 pcs. – contour cell packaging (7) – cardboard packs.
7 pcs. – contour cell packaging (8) – cardboard packs.
7 pcs. – contour cell packaging (9) – cardboard packs.
7 pcs. – contour cell packaging (10) – cardboard packs.
10 pcs. – contour cell packaging (1) – cardboard packs.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
10 pcs. – contour cell packaging (4) – cardboard packs.
10 pcs. – contour cell packaging (5) – cardboard packs.
10 pcs. – contour cell packaging (6) – cardboard packs.
10 pcs. – contour cell packaging (7) – cardboard packs.
10 pcs. – contour cell packaging (8) – cardboard packs.
10 pcs. – contour cell packaging (9) – cardboard packs.
10 pcs. – contour cell packaging (10) – cardboard packs.
15 pcs. – contour cell packaging (1) – cardboard packs.
15 pcs. – contour cell packaging (2) – cardboard packs.
15 pcs. – contour cell packaging (3) – cardboard packs.
15 pcs. – contour cell packaging (4) – cardboard packs.
15 pcs. – contour cell packaging (5) – cardboard packs.
15 pcs. – contour cell packaging (6) – cardboard packs.
15 pcs. – contour cell packaging (7) – cardboard packs.
15 pcs. – contour cell packaging (8) – cardboard packs.
15 pcs. – contour cell packaging (9) – cardboard packs.
15 pcs. – contour cell packaging (10) – cardboard packs.
20 pcs. – contour cell packaging (1) – cardboard packs.
20 pcs. – contour cell packaging (2) – cardboard packs.
20 pcs. – contour cell packaging (3) – cardboard packs.
20 pcs. – contour cell packaging (4) – cardboard packs.
20 pcs. – contour cell packaging (5) – cardboard packs.
20 pcs. – contour cell packaging (6) – cardboard packs.
20 pcs. – contour cell packaging (7) – cardboard packs.
20 pcs. – contour cell packaging (8) – cardboard packs.
20 pcs. – contour cell packaging (9) – cardboard packs.
20 pcs. – contour cell packaging (10) – cardboard packs.
30 pcs. – contour cell packaging (1) – cardboard packs.
30 pcs. – contour cell packaging (2) – cardboard packs.
30 pcs. – contour cell packaging (3) – cardboard packs.
30 pcs. – contour cell packaging (4) – cardboard packs.
30 pcs. – contour cell packaging (5) – cardboard packs.
30 pcs. – contour cell packaging (6) – cardboard packs.
30 pcs. – contour cell packaging (7) – cardboard packs.
30 pcs. – contour cell packaging (8) – cardboard packs.
30 pcs. – contour cell packaging (9) – cardboard packs.
30 pcs. – contour cell packaging (10) – cardboard packs.
10 pcs. – jars (1) – cardboard packs.
20 pcs. – jars (1) – cardboard packs.
30 pcs. – jars (1) – cardboard packs.
40 pcs. – jars (1) – cardboard packs.
50 pcs. – jars (1) – cardboard packs.
60 pcs. – jars (1) – cardboard packs.
70 pcs. – jars (1) – cardboard packs.
80 pcs. – jars (1) – cardboard packs.
90 pcs. – jars (1) – cardboard packs.
100 pcs. – jars (1) – cardboard packs.
120 pcs. – jars (1) – cardboard packs.
140 pcs. – jars (1) – cardboard packs.
150 pcs. – jars (1) – cardboard packs.
160 pcs. – jars (1) – cardboard packs.
180 pcs. – jars (1) – cardboard packs.
200 pcs. – jars (1) – cardboard packs.
210 pcs. – jars (1) – cardboard packs.
240 pcs. – jars (1) – cardboard packs.
270 pcs. – jars (1) – cardboard packs.
300 pcs. – jars (1) – cardboard packs.

Tablets from light yellow to yellow with a greenish tint, round, flat-cylindrical, with a bevel and a score line; the presence of “marbling” and small inclusions is allowed.

	1 tab.
Meloxicam	15 mg

Excipients: lactose monohydrate (milk sugar), crospovidone (kollidon CL, kollidon CL-M), talc, magnesium stearate, microcrystalline cellulose (101).

Meloxicam Velpharm [Elzapharm, LLC (Russia)]
Solution for intramuscular administration 10 mg/1 ml: 1.5 ml amp. 3, 5, 6 or 10 pcs.

Marketing Authorization Holder

Elzapharm, LLC (Russia)

Manufactured By

Velpharm, LLC (Russia)

Dosage Form

Meloxicam Velpharm

Solution for intramuscular administration 10 mg/1 ml: 1.5 ml amp. 3, 5, 6 or 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intramuscular administration transparent or slightly opalescent, yellow with a greenish tint.

	1 ml
Meloxicam	10 mg

Excipients: meglumine, tetraglycol (glycofurfuryl, glycofurol), poloxamer 188, sodium chloride, glycine, 1M sodium hydroxide solution, water for injection.

1.5 ml – glass ampoules (3) – contour cell packs (1) – cardboard packs.
1.5 ml – glass ampoules (3) – contour cell packs (2) – cardboard packs.
1.5 ml – glass ampoules (5) – contour cell packs (1) – cardboard packs.
1.5 ml – glass ampoules (5) – contour cell packs (2) – cardboard packs.

Meloxicam-AKOS [Sintez PJSC (Russia)]
Solution for intramuscular injection 10 mg/ml: amp. 3 or 5 pcs.

Marketing Authorization Holder

Sintez PJSC (Russia)

Dosage Form

Meloxicam-AKOS

Solution for intramuscular injection 10 mg/ml: amp. 3 or 5 pcs.

Dosage Form, Packaging, and Composition

Solution for intramuscular injection transparent yellow with a greenish tint.

	1 ml
Meloxicam	10 mg

Excipients: sodium chloride, glycine, glycofurfuryl, poloxamer 188, meglumine, sodium hydroxide, water for injection.

1.5 ml – colorless glass ampoules with a capacity of 2 ml (3 or 5) – contour cell packs (1 or 2) – cardboard packs.

Meloxicam-AKOS [Sintez PJSC (Russia)]
Tablets 7.5 mg: 10, 20, 30, 50 or 100 pcs.
Tablets 15 mg: 10, 20, 30, 50 or 100 pcs.

Marketing Authorization Holder

Sintez PJSC (Russia)

Dosage Forms

	Meloxicam-AKOS	Tablets 7.5 mg: 10, 20, 30, 50 or 100 pcs.
		Tablets 15 mg: 10, 20, 30, 50 or 100 pcs.

Dosage Form, Packaging, and Composition

	1 tab.
Meloxicam	7.5 mg

Excipients: microcrystalline cellulose (type 12), lactose monohydrate, crospovidone, talc, colloidal silicon dioxide (aerosil), magnesium stearate.

	1 tab.
Meloxicam	15 mg

Excipients: microcrystalline cellulose (type 12), lactose monohydrate, crospovidone, talc, colloidal silicon dioxide (aerosil), magnesium stearate.

Meloxicam-Akrikhin [Polpharma Pharmaceutical Works, Sa (Poland)]
Solution for intramuscular injection 10 mg/1 ml: amp. 1.5 ml 3 or 5 pcs.

Marketing Authorization Holder

Polpharma Pharmaceutical Works, Sa (Poland)

Manufactured By

Pharmaceutical Works “Polpharma”, SA (Poland)

Labeled By

Pharmaceutical Works “POLPHARMA”, SA (Poland)

Akrikhin Chemical and Pharmaceutical Plant, JSC (Russia)

Quality Control Release

Pharmaceutical Works “POLPHARMA”, SA (Poland)

Dosage Form

Meloxicam-Akrikhin

Solution for intramuscular injection 10 mg/1 ml: amp. 1.5 ml 3 or 5 pcs.

Dosage Form, Packaging, and Composition

Solution for intramuscular administration yellow or greenish-yellow, transparent, with a characteristic odor.

	1 ml	1 amp.
Meloxicam	10 mg	15 mg

Excipients: meglumine – 6.25 mg, glycofurol – 100 mg, poloxamer 188 – 50 mg, sodium chloride – 3 mg, glycine – 5 mg, sodium hydroxide – 0.152 mg, water for injection – up to 1 ml.

1.5 ml – glass ampoules with a capacity of 2 ml (3) – contour cell packs (1) – cardboard packs.
1.5 ml – glass ampoules with a capacity of 2 ml (5) – contour cell packs (1) – cardboard packs.

Meloxicam-Akrikhin [Akrikhin Chemical and Pharmaceutical Plant, JSC (Russia)]
Tablets 7.5 mg: 10, 20 or 30 pcs.
Tablets 15 mg: 10, 20 or 30 pcs.

Marketing Authorization Holder

Akrikhin Chemical and Pharmaceutical Plant, JSC (Russia)

Manufactured By

Unichem Laboratories, Ltd. (India)

Dosage Forms

	Meloxicam-Akrikhin	Tablets 7.5 mg: 10, 20 or 30 pcs.
		Tablets 15 mg: 10, 20 or 30 pcs.

Dosage Form, Packaging, and Composition

Tablets light yellow, round, with bevels, with one side convex, with an engraving “7.5” on the other side concave with a deep score.

	1 tab.
Meloxicam	7.5 mg

Excipients: lactose monohydrate – 182.65 mg, microcrystalline cellulose – 37.5 mg, sodium citrate – 11.1 mg, crospovidone – 7.5 mg, colloidal silicon dioxide – 2.5 mg, magnesium stearate – 1.25 mg.

10 pcs. – blisters (1) – cardboard packs.
10 pcs. – blisters (2) – cardboard packs.
10 pcs. – blisters (3) – cardboard packs.

Tablets light yellow, round, with bevels, with one side convex with an engraving “15”, on the other side concave with a deep score.

	1 tab.
Meloxicam	15 mg

Excipients: lactose monohydrate – 365.3 mg, microcrystalline cellulose – 75 mg, sodium citrate – 22.2 mg, crospovidone – 15 mg, colloidal silicon dioxide – 5 mg, magnesium stearate – 2.5 mg.

10 pcs. – blisters (1) – cardboard packs.
10 pcs. – blisters (2) – cardboard packs.
10 pcs. – blisters (3) – cardboard packs.

Meloxicam-Lekpharm [Lekpharm, SOOO (Republic of Belarus)]
Solution for intramuscular injection 10 mg/1 ml: amp. 1.5 ml 3 or 5 pcs.

Marketing Authorization Holder

Lekpharm, SOOO (Republic of Belarus)

Dosage Form

Meloxicam-Lekpharm

Solution for intramuscular injection 10 mg/1 ml: amp. 1.5 ml 3 or 5 pcs.

Dosage Form, Packaging, and Composition

Solution for intramuscular administration transparent, yellow with a greenish tint.

	1 ml
Meloxicam	10 mg

Excipients: meglumine – 6.25 mg, tetrahydrofurfuryl macrogol (glycofurol) – 100 mg, poloxamer 188 – 50 mg, glycine – 5 mg, sodium chloride – 3.5 mg, sodium hydroxide (as a 1M solution) – to pH 8.8±0.2, water for injection – up to 1 ml.

1.5 ml – colorless glass ampoules (3) – contour cell packs (1) – cardboard packs.
1.5 ml – colorless glass ampoules (5) – contour cell packs (1) – cardboard packs.

Meloxicam-Prana [Pranapharm, LLC (Russia)]
Tablets 7.5 mg: 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 pcs.
Tablets 15 mg: 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 pcs.

Marketing Authorization Holder

Pranapharm, LLC (Russia)

Dosage Forms

	Meloxicam-Prana	Tablets 7.5 mg: 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 pcs.
		Tablets 15 mg: 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 pcs.

Dosage Form, Packaging, and Composition

Tablets from light yellow to yellow with a greenish tint, flat-cylindrical in shape; slight marbling is allowed.

	1 tab.
Meloxicam	7.5 mg

Excipients: lactose monohydrate, microcrystalline cellulose, magnesium stearate, corn starch, colloidal silicon dioxide, sodium croscarmellose.

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
50 pcs. – polymer jars (1) – cardboard packs.
60 pcs. – polymer jars (1) – cardboard packs.
70 pcs. – polymer jars (1) – cardboard packs.
80 pcs. – polymer jars (1) – cardboard packs.
90 pcs. – polymer jars (1) – cardboard packs.
100 pcs. – polymer jars (1) – cardboard packs.

Tablets from light yellow to yellow with a greenish tint, flat-cylindrical in shape, have a dividing score on one side; slight marbling is allowed.

	1 tab.
Meloxicam	15 mg

Excipients: lactose monohydrate, microcrystalline cellulose, magnesium stearate, corn starch, colloidal silicon dioxide, sodium croscarmellose.

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
50 pcs. – polymer jars (1) – cardboard packs.
60 pcs. – polymer jars (1) – cardboard packs.
70 pcs. – polymer jars (1) – cardboard packs.
80 pcs. – polymer jars (1) – cardboard packs.
90 pcs. – polymer jars (1) – cardboard packs.
100 pcs. – polymer jars (1) – cardboard packs.

Meloxicam-SZ [Severnaya Zvezda, CJSC (Russia)]
Tablets 7.5 mg: 10, 20 or 30 pcs.

Marketing Authorization Holder

Severnaya Zvezda, CJSC (Russia)

Dosage Form

Meloxicam-SZ

Tablets 7.5 mg: 10, 20 or 30 pcs.

Dosage Form, Packaging, and Composition

Tablets from light yellow to light yellow with a greenish tint, flat-cylindrical, slight “marbling” is allowed.

	1 tab.
Meloxicam	7.5 mg

Excipients: lactose, microcrystalline cellulose, sodium citrate, polyvinylpyrrolidone (povidone), colloidal silicon dioxide, crospovidone, magnesium stearate.

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
20 pcs. – glass jars (1) – cardboard packs.
30 pcs. – glass jars (1) – cardboard packs.
20 pcs. – polymer jars (1) – cardboard packs.
30 pcs. – polymer jars (1) – cardboard packs.
20 pcs. – polymer bottles (1) – cardboard packs.
30 pcs. – polymer bottles (1) – cardboard packs.

Meloxicam-SZ [Severnaya Zvezda, CJSC (Russia)]
Tablets 15 mg: 10, 20 or 30 pcs.

Marketing Authorization Holder

Severnaya Zvezda, CJSC (Russia)

Dosage Form

Meloxicam-SZ

Tablets 15 mg: 10, 20 or 30 pcs.

Dosage Form, Packaging, and Composition

Tablets from light yellow to light yellow with a greenish tint, flat-cylindrical, slight “marbling” is allowed.

	1 tab.
Meloxicam	15 mg

Excipients: lactose, microcrystalline cellulose, sodium citrate, polyvinylpyrrolidone (povidone), colloidal silicon dioxide, crospovidone, magnesium stearate.

Meloxicam-Teva [Teva Pharmaceutical Industries, Ltd. (Israel)]
Tablets 7.5 mg: 10 or 20 pcs.

Marketing Authorization Holder

Teva Pharmaceutical Industries, Ltd. (Israel)

Manufactured By

Teva Pharmaceutical Works, Private Limited Company (Hungary)

Dosage Form

Meloxicam-Teva

Tablets 7.5 mg: 10 or 20 pcs.

Dosage Form, Packaging, and Composition

Tablets yellow, round, flat-cylindrical, with a bevel and slight “marbling”; with a dividing score on one side and an engraving “MLX 7.5” on the other side.

	1 tab.
Meloxicam	7.5 mg

Excipients: lactose monohydrate – 77.2 mg, microcrystalline cellulose – 56 mg, sodium citrate dihydrate – 18 mg, povidone K30 – 6 mg, crospovidone – 12 mg, colloidal silicon dioxide – 1.5 mg, magnesium stearate – 1.8 mg.

10 pcs. – blisters (1) – cardboard packs.^x
10 pcs. – blisters (2) – cardboard packs.^x

^x with first opening control

Meloxicam-Teva [Teva Pharmaceutical Industries, Ltd. (Israel)]
Tablets 15 mg: 10 or 20 pcs.

Marketing Authorization Holder

Teva Pharmaceutical Industries, Ltd. (Israel)

Manufactured By

Teva Pharmaceutical Works, Private Limited Company (Hungary)

Dosage Form

Meloxicam-Teva

Tablets 15 mg: 10 or 20 pcs.

Dosage Form, Packaging, and Composition

Tablets yellow, oval, with slight “marbling”; with a dividing score on one side and an engraving “MLX 15” on the other side.

	1 tab.
Meloxicam	15 mg

Excipients: lactose monohydrate – 69.7 mg, microcrystalline cellulose – 56 mg, sodium citrate dihydrate – 18 mg, povidone K30 – 6 mg, crospovidone – 12 mg, colloidal silicon dioxide – 1.5 mg, magnesium stearate – 1.8 mg.

10 pcs. – blisters (1) – cardboard packs^x.
10 pcs. – blisters (2) – cardboard packs^x.

^x with first opening control

Meloxicam-VERTEX [Vertex, JSC (Russia)]
Tablets 7.5 mg: 20 pcs.
Tablets 15 mg: 20 pcs.

Marketing Authorization Holder

Vertex, JSC (Russia)

Dosage Forms

	Meloxicam-VERTEX	Tablets 7.5 mg: 20 pcs.
		Tablets 15 mg: 20 pcs.

Dosage Form, Packaging, and Composition

Tablets from light yellow to yellow in color, round, flat-cylindrical, with a bevel; the presence of marbling and small inclusions is allowed.

	1 tab.
Meloxicam	7.5 mg

Excipients: lactose monohydrate – 88 mg, microcrystalline cellulose – 62.4 mg, sodium citrate dihydrate – 7.5 mg, sodium carboxymethyl starch – 7.2 mg, povidone K30 – 3.6 mg, colloidal silicon dioxide – 2 mg, calcium stearate – 1.8 mg.

10 pcs. – contour cell packs (2) – cardboard packs.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – high-density polyethylene jars (1) – cardboard packs.

Tablets from light yellow to yellow in color, round, flat-cylindrical, with a bevel and a score; the presence of marbling and small inclusions is allowed.

	1 tab.
Meloxicam	15 mg

Excipients: lactose monohydrate – 176 mg, microcrystalline cellulose – 124.8 mg, sodium citrate dihydrate – 15 mg, sodium carboxymethyl starch – 14.4 mg, povidone K30 – 7.2 mg, colloidal silicon dioxide – 4 mg, calcium stearate – 3.6 mg.

10 pcs. – contour cell packs (2) – cardboard packs.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – high-density polyethylene jars (1) – cardboard packs.

Meloxicam-Xantis [Xantis Pharma, Limited (Cyprus)]
Tablets 7.5 mg: 10, 20, 30, 40, or 50 pcs.
Tablets 15 mg: 10, 20, 30, 40, or 50 pcs.

Marketing Authorization Holder

Xantis Pharma, Limited (Cyprus)

Manufactured By

Alsi Pharma, JSC (Russia)

Dosage Forms

	Meloxicam-Xantis	Tablets 7.5 mg: 10, 20, 30, 40, or 50 pcs.
		Tablets 15 mg: 10, 20, 30, 40, or 50 pcs.

Dosage Form, Packaging, and Composition

Tablets light yellow with a greenish tint, round, flat-cylindrical, with a bevel.

	1 tab.
Meloxicam	7.5 mg

Excipients: microcrystalline cellulose (type 102) – 61.3 mg, pregelatinized starch – 30 mg, sodium citrate – 20 mg, colloidal silicon dioxide (aerosil) – 0.6 mg, magnesium stearate – 0.6 mg.

Tablets light yellow with a greenish tint, round, flat-cylindrical, with a bevel and a score.

	1 tab.
Meloxicam	15 mg

Excipients: microcrystalline cellulose (type 102) – 122.6 mg, pregelatinized starch – 60 mg, sodium citrate – 40 mg, colloidal silicon dioxide (aerosil) – 1.2 mg, magnesium stearate – 1.2 mg.

Medixlife (Author)

View all posts Profile link